The U.S. Supreme Court last week breathed new life into a long-running Federal Trade Commission campaign against "pay for delay" agreements between competing brand-name and generic drug manufacturers that put off the production of generics in return for cash.
But in the aftermath of the June 17 ruling in FTC v. Actavis, it is uncertain whether the agency can resume the litigation program at full strength, and also whether drug makers will scuttle the deals or gussy them up to make them more acceptable to lower courts.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
